Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | GNPAT | O15228 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30477906 | 0.94 | MME (0.41) | MMEACEENPEPFNTAFNTB | |
| SCHEMBL30477910 | 0.94 | MME (0.41) | MMEACEENPEPFNTAFNTB | |
| SCHEMBL30477918 | 0.94 | MME (0.41) | MMEACEENPEPFNTAFNTB | |
| SCHEMBL30477908 | 0.94 | MME (0.41) | MMEACEENPEPFNTAFNTB | |
| SCHEMBL30477922 | 0.94 | MME (0.41) | MMEACEENPEPFNTAFNTB | |
| SCHEMBL30477916 | 0.94 | MME (0.41) | MMEACEENPEPFNTAFNTB | |
| SCHEMBL30798035 | 0.93 | MME (0.41) | MMEGNPATENPEPPLA2G2A | |
| SCHEMBL31229006 | 0.93 | ACE (0.38) | MMEACEFNTAFNTBPGGT1B | |
| SCHEMBL8417585 | 0.93 | ACE (0.40) | MMEACEFNTAFNTBPGGT1B | |
| SCHEMBL21828629 | 0.93 | ACE (0.40) | MMEACEFNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415995-B2 | Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders | NORTHWESTERN UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| US-20230045284-A1 | BACTERIAL TOXINS AND USES THEREOF AS RAS SPECIFIC PROTEASES FOR TREATING CELL PROLIFERATION DISEASES AND DISORDERS | NORTHWESTERN UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| US-11401304-B2 | Cyclic NTCP-targeting peptides and their uses as entry inhibitors | Ruprecht-Karls-Universität Heidelberg (DE) | 2022-08-02 | — | — | US | disclosed |
| CN-108367047-B | Cyclic NTCP targeting peptides and their use as entry inhibitors | 鲁普莱希特-卡尔斯-海德堡大学 | 2022-07-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401304-B2 | Cyclic NTCP-targeting peptides and their uses as entry inhibitors | HAVCR2, VIP, HDGF | MME 80/4885ACE 1219/4885FOLH1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.